|
||
| Viagra® is indicated for the treatment of erectile dysfunction (ED) which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. | ||
|
||
|
ADVERSE REACTIONS: Headache; flushing/vasodilation; dizziness; abnormal vision; chromatopsia; palpitation; rhinitis; dyspepsia.
INTERACTIONS: Nitric oxide donors or nitrates and nitrites in any form; reduction in sildenafil clearance when co-administered with CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, cimetidine, saquinavir, ritonavir); co-administration with α-blocker may lead to symptomatic hypotension. |
|
||
|
Adults: 50 mg approximately 1 hour before sexual activity; based on effectiveness and toleration, dose may be increased to the maximum recommended dose of 100 mg or decreased to 25 mg.
Elderly: Initially 25 mg, may be increased to 50–100 mg based on effectiveness and tolerability. |
|
||
| 25 mg, 50 mg, 100 mg (Not all strengths may be marketed) |
|
||
| Tablets: 50 mg x 1's, 50 mg x 4's, 100 mg x 1's, 100 mg x 4's |
|
||
|
CONTRAINDICATIONS: Viagra® is contraindicated in patients with known hypersensitivity to the active substance or to any of the drug’s excipients; patients concurrently using nitric oxide donors, organic nitrates or nitrites in any form either regularly or intermittently; co-administration with α-blockers.
SPECIAL PRECAUTIONS: Viagra® is not for use in men for whom sexual activity is inadvisable; patients with increased susceptibility to vasodilators; patients at risk of non-arteritic anterior ischemic optic neuropathy (NAION); retinitis pigmentosa; bleeding disorders or active peptic ulceration; anatomical deformation of the penis or in patients who have conditions that may predispose them to priapism; combination with other treatments for ED; co-administration with α-blockers. ADVERSE REACTIONS: Headache; flushing/vasodilation; dizziness; abnormal vision; chromatopsia; palpitation; rhinitis; dyspepsia. POST-MARKETING ADVERSE REACTIONS: hypersensitivity reaction (including skin rash); seizure, seizure recurrence; tachycardia; hypotension, syncope, epistaxis; vomiting; eye pain/red/bloodshot eyes; prolonged erection/priapism. PREGNANCY and LACTATION: Viagra® is not indicated for use in women. There are no adequate and well-controlled studies in pregnant or lactating women. Please refer to the full prescribing information for more safety information. |
||
Please review the full product information or package insert before prescribing. |
|
||
|
1. Viagra® (sildenafil citrate) Prescribing Information. Pfizer Corporation Hong Kong Ltd: 21 December 2007.
2. Kell P. J Sex Med. 2006;3(Suppl 3):273. 3. Gil A, Martinez E, Oyaguez I, Palacios G, Rejas J. Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use. Int J Impot Res. 2001;13(6):338-347. |
||
Please review the full product information or package insert before prescribing.
|
